Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children

Sinovac

Status and phase: Completed; Phase 1

Conditions: Hand-foot-mouth Disease; Infection; Viral, Enterovirus

Treatments: Biological: Placebo; Biological: 200U inactivated Enterovirus Type 71 Vaccine; Biological: 400U inactivated Enterovirus Type 71 Vaccine; Biological: 100U inactivated Enterovirus Type 71 Vaccine

Study type: Interventional

Funder types: Industry

Identifiers

NCT01273246

EV71-1001-Ib

Details and patient eligibility

About

A Phase I clinical trialto evaluate the safety of an Inactivated Enterovirus Type 71 Vaccine in healthy children (3-11y) and infants (6-35m).

Full description

36 eligible children aged from 3 to 11 years and 96 eligible infants aged from 6 to 35 months will be enrolled in the study, they will be randomized to receive different dosage of vaccine candidate or placebo to evaluate the safety of this vaccine

Enrollment: 132 patients

Sex: All

Ages: 6 months to 11 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy males and females, aged from 6 months to 11 years old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
2. Provided legal identification for the sake of recruitment.
3. Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed consents.
4. Birth weight more than 2500 grams

Exclusion criteria

1. Histroy of Hand-foot-mouth Disease
2. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
4. Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
5. Epilepsy, seizures or convulsions history, or family history of mental illness
6. Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
7. History of asthma, angioedema, diabetes or malignancy
8. History of thyroidectomy or thyroid disease that required medication within the past 12 months
9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
10. Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
11. Acute illness or acute exacerbation of chronic disease within the past 7 days
12. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
13. History of any blood products within 3 months
14. Administration of any live attenuated vaccine within 28 days
15. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
16. Axillary temperature > 37.0 centigrade before vaccination
17. Abnormal laboratory parameters before vaccination
18. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

132 participants in 10 patient groups, including a placebo group

Children Group 1: 200U EV71 vaccine

Experimental group

Description:

12 children received 3 doses of 200U EV71 vaccine 28 days apart

Treatment:

Biological: 200U inactivated Enterovirus Type 71 Vaccine

Children Group 1: Placebo

Placebo Comparator group

Description:

6 children received 3 doses of placebo 28 days apart

Treatment:

Biological: Placebo

Children Group 2: 400U EV71 vaccine

Experimental group

Description:

12 children received 3 doses of 400U EV71 vaccine 28 days apart

Treatment:

Biological: 400U inactivated Enterovirus Type 71 Vaccine

Children Group 2: Placebo

Placebo Comparator group

Description:

6 children received 3 doses of placebo 28 days apart

Treatment:

Biological: Placebo

Infants Group 1: 100U EV71 vaccine

Experimental group

Description:

24 infants received 3 doses of 100U EV71 vaccine 28 days apart

Treatment:

Biological: 100U inactivated Enterovirus Type 71 Vaccine

Infants Group 1: Placebo

Placebo Comparator group

Description:

8 infants received 3 doses of placebo 28 days apart

Treatment:

Biological: Placebo

Infants Group 2: 200U EV71 vaccine

Experimental group

Description:

24 infants received 3 doses of 200U EV71 vaccine 28 days apart

Treatment:

Biological: 200U inactivated Enterovirus Type 71 Vaccine

Infants Group 2: Placebo

Placebo Comparator group

Description:

8 infants received 3 doses of placebo 28 days apart

Treatment:

Biological: Placebo

Infants Group 3: 400U EV71 vaccine

Experimental group

Description:

24 infants received 3 doses of 400U EV71 vaccine 28 days apart

Treatment:

Biological: 400U inactivated Enterovirus Type 71 Vaccine

Infants Group 3: Placebo

Placebo Comparator group

Description:

8 infants received 3 doses of placebo 28 days apart

Treatment:

Biological: Placebo